A non-internalised CD38-binding radiolabelled single-domain antibody fragment to monitor and treat multiple myeloma
Abstract Background Antibody-based therapies targeting CD38 are currently used as single agents as well as in combination regimens for multiple myeloma, a malignant plasma cell disorder. In this study, we aimed to develop anti-CD38 single-domain antibodies (sdAbs) that can be used to trace CD38+ tum...
Guardado en:
Autores principales: | Elodie Duray, Margaux Lejeune, Frederic Baron, Yves Beguin, Nick Devoogdt, Ahmet Krasniqi, Yoline Lauwers, Yong Juan Zhao, Matthias D’Huyvetter, Mireille Dumoulin, Jo Caers |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
BMC
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/6b141013e0604fe3b0f374aa12371db3 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma
por: Bhutani D, et al.
Publicado: (2017) -
BCL2 Family Inhibitors in the Biology and Treatment of Multiple Myeloma
por: Gupta VA, et al.
Publicado: (2021) -
Assessment and monitoring of patients receiving chemotherapy for multiple myeloma: strategies to improve outcomes
por: Faiman B, et al.
Publicado: (2016) -
Cyclophosphamide-glucocorticoids versus lenalidomide-dexamethasone as treatment for multiple myeloma at first relapse after autologous stem cell transplantation – a retrospective analysis
por: Russell Sterrett, et al.
Publicado: (2021) -
Smoldering multiple myeloma: prevalence and current evidence guiding treatment decisions
por: Blum A, et al.
Publicado: (2018)